Cara Therapeutics

Read more
Derek Chalmers's photo - President & CEO of Cara Therapeutics

President & CEO

Derek Chalmers

CEO Approval Rating

87/100

Founded:

2004

Status:

PublicIndependent CompanyNASDAQCARA

CARA THERAPEUTICS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Cara Therapeutics's company profile
Derek Chalmers's photo - President & CEO of Cara Therapeutics

Derek Chalmers

President & CEO

87/100
55
$98M
$123.3M
View Profile
1
Cara Therapeutics's Competitor - Innocoll logo
Louis Pascarella's photo - President & CEO of Innocoll

Louis Pascarella

President & CEO

83/100
105
$88.5M
$4.4M
View Profile
2
Cara Therapeutics's Competitor - Targa Therapeutics Corp. logo
Gary D Aronson's photo - Co-Founder & CEO of Targa Therapeutics Corp.

Gary D Aronson

Co-Founder & CEO

70/100
- -
View Profile
3
Cara Therapeutics's Competitor - eNeura logo
Donald Pearl's photo - CEO of eNeura

Donald Pearl

CEO

79/100
26
$53.6M
$11.2M
View Profile
4
Cara Therapeutics's Competitor - Five Prime logo
Thomas Civik's photo - President & CEO of Five Prime

Thomas Civik

President & CEO

83/100
168
$165.2M
$13.2M
View Profile
5
Cara Therapeutics's Competitor - Sirenas logo
Eduardo Esquenazi's photo - Founder & CEO of Sirenas

Eduardo Esquenazi

Founder & CEO

81/100
69
$1.5M
$5M
View Profile
6
Cara Therapeutics's Competitor - Quartet Medicine logo
Gerhard Koenig's photo - CEO of Quartet Medicine

Gerhard Koenig

CEO

68/100
35
$23.3M
$ < 1M
View Profile
7
Cara Therapeutics's Competitor - Procakes High Protein Pancake Mix logo
CEO Avatar

CEO

- -
44
- -
$1.1M
View Profile
8
Cara Therapeutics's Competitor - PanOptica logo
Paul G. Chaney's photo - President & CEO of PanOptica

Paul G. Chaney

President & CEO

87/100
100
$81.7M
$8.9M
View Profile
9
Cara Therapeutics's Competitor - Adynxx logo
Rick Orr's photo - President & CEO of Adynxx

Rick Orr

President & CEO

69/100
81
$21.6M
$6.7M
View Profile

Missing a competitor? Contribute!

Innocoll is Cara Therapeutics's #1 rival. Innocoll is a Private company that was founded in Newtown Square, Pennsylvania in 1985. Innocoll competes in the Pharmaceuticals field. Innocoll has 50 more employees vs. Cara Therapeutics.

Targa Therapeutics Corp. is perceived as one of Cara Therapeutics's biggest rivals. Targa Therapeutics Corp. was founded in 2002, and is headquartered in San Diego, California. Targa Therapeutics Corp. is in the field. Targa Therapeutics Corp. generates $ less revenue vs. Cara Therapeutics.

eNeura is a top competitor of Cara Therapeutics. eNeura is a Private company that was founded in 2012 in Baltimore, Maryland. eNeura competes in the Health Care Services industry. Compared to Cara Therapeutics, eNeura has 29 fewer employees.

Cara Therapeutics Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$123.3M

Cara Therapeutics's revenue is the ranked 1st among it's top 10 competitors. The top 10 competitors average 19.4M. Over the last three quarters, Cara Therapeutics's revenue has decreased by 79.1%. Specifically, in Q1 2021's revenue was $1.9M; in Q4 2020, it was $112.1M; in Q3 2020, it was $9.3M.

Cara Therapeutics Acquisitions

No recent acquisitions found related to Cara Therapeutics

Cara Therapeutics Funding History

Since Cara Therapeutics was founded in 2004, it has participated in 4 rounds of funding. In total Cara Therapeutics has raised $98.0M. Cara Therapeutics' last funding round was on Jan 2014 for a total of $55.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Jan 2014
$55M
-
Series D
Jul 2010
$15M
Equity
May 2008
$9M
-
Series C
Nov 2006
$19M

Since Cara Therapeutics was founded in 2004, it has participated in 4 rounds of funding. In total Cara Therapeutics has raised $98.0M. Cara Therapeutics' last funding round was on Jan 2014 for a total of $55.0M

Cara Therapeutics Investments

No recent investments found related to Cara Therapeutics

Cara Therapeutics News

August 12, 2021MarketScreener

Investor Fact Sheet

(marketscreener.com) About Us Pipeline: Commercial Opportunity: Established KORSUVA IV Commercial Par... See more »
June 11, 2021Nonwovens Industry

Enteris BioPharma Receives $10M Milestone from Cara Therapeutics

Third milestone payment related to the development of Oral KORSUVA.... See more »
June 11, 2021Contract Pharma

Enteris BioPharma Receives $10M Milestone from Cara Therapeutics

Third milestone payment related to the development of Oral KORSUVA.... See more »
June 3, 2021Benzinga

Return On Capital Employed Insights

During Q1, Cara Therapeutics (NASDAQ:CARA) brought in sales totaling $1.94 million. However, earnings... See more »
May 25, 2021Benzinga

Cara Therapeutics to Present at the Jefferies Healthcare Conference

STAMFORD, Conn., May 25, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmac... See more »

Cara Therapeutics Press Releases

November 2, 2020GlobeNewswire

Cara Therapeutics to Announce Third Quarter 2020 Financial Results on November 9, 2020

STAMFORD, Conn., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharm... See more »
October 27, 2020PR Newswire

SWK Holdings' Subsidiary, Enteris BioPharma, Receives Milestone Payment from Cara Therapeutics

DALLAS, Oct. 27, 2020 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focuse... See more »
May 27, 2020GlobeNewswire

Cara Therapeutics to Present at the Jefferies Virtual Healthcare Conference

STAMFORD, Conn., May 27, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharma... See more »
January 8, 2020GlobeNewswire

Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharm... See more »
December 6, 2019StreetInsider

CytomX Therapeutics Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTM... See more »
May 8, 2019GlobeNewswire

Cara Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

STAMFORD, Conn., May 08, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharma... See more »

Social Media

Cara Therapeutics Headquarters

4 Stamford Plaza 107 Elm Street 9th Floor

Stamford, Connecticut06902

203-406-3700

Driving Directions »

Trending Companies

Cara Therapeutics Summary

ABOUT

Overview

Cara Therapeutics, Inc. (CARA - NASDAQ) is an American biotechnology company which specializes in developing and commercializing proprietary compounds to treat inflammation, pain, and pruritus. Currently, its most advanced compound, CR845, is being te...

CEO

Cara Therapeutics's President & CEO, Derek Chalmers, currently has an approval rating of 87%. Cara Therapeutics's primary competitors are Innocoll, Targa Therapeutics Corp. & eNeura.

Frequently Asked Questions about Cara Therapeutics

  1. When was Cara Therapeutics founded?

    Cara Therapeutics was founded in 2004
  2. Who is Cara Therapeutics's CEO?

    Cara Therapeutics's CEO is Derek Chalmers
  3. How much revenue does Cara Therapeutics generate?

    Cara Therapeutics generates $123.3M in revenue
  4. How much funding does Cara Therapeutics have?

    Cara Therapeutics has historically raised $98M in funding
  1. Where is Cara Therapeutics's headquarters?

    Cara Therapeutics's headquarters is in Stamford Connecticut, USA
  2. How many employees does Cara Therapeutics have?

    Cara Therapeutics has 55 employees
  3. What sector does Cara Therapeutics operate in?

    Cara Therapeutics is in Biotechnology
  4. Who are Cara Therapeutics's competitors?

    Cara Therapeutics's top competitors are Innocoll, Targa Therapeutics Corp., eNeura